The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants-a multi-site prospective cohort study.
Aimee L DavidsonUwe DresselSarah NorrisDaffodil M CansonDylan M GlubbCristina FortunoGeorgina E HollwayMichael T ParsonsMiranda E VidgenOliver HolmesLambros T KoufariotisVanessa LakisConrad LeonardScott WoodQinying XuAmy E McCart ReedHilda A PickettMohammad K Al-ShinnagRachel L AustinJo BurkeElisa J CopsCassandra B NicholsAnnabel GoodwinMarion T HarrisMegan J HigginsEmilia L IpCatherine Kiraly-BorriChiyan LauJulia L MansourMichael W MillwardMelissa J MonnikNicholas S PachterAbiramy RagunathanRachel D SusmanSharron L TownshendAlison H TrainerSimon L TrothKatherine M TuckerMathew J WallisMaie WalshRachel A WilliamsIngrid M WinshipFelicity NewellEmma TudiniJohn V PearsonNicola K PoplawskiHelen G Mar FanPaul A JamesAmanda B SpurdleNicola WaddellRobyn L WardPublished in: Genome medicine (2023)
These findings make a case for replacing conventional testing with WGS to deliver clinically important benefits for cancer patients and families. The uptake of such an approach will depend on the perspectives of different payers on affordability.